Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells 32,450 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $243.00 on Friday. The stock has a market capitalization of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $252.87. The company has a 50 day moving average price of $159.86 and a 200 day moving average price of $164.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.40) earnings per share. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $283.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.09.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $390,438,000. Capital International Investors boosted its stake in Alnylam Pharmaceuticals by 15.8% in the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares during the period. Wellington Management Group LLP grew its position in Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares in the last quarter. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. Finally, Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.